Publications by authors named "Elizabeth Christie"

Claim this Profile
T
Targeting ALC1 can safely expand the therapeutic utility of PARP inhibitors across high-grade serous ovarian cancers.
Lindsey N Aubuchon, Deanna H Wong, Natasha M Ramakrishnan, Rohan Reddy, Amanda Compadre, Elizabeth L Christie

bioRxiv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biology of ovarian cancer: Models, microenvironment, and therapeutics: 15th Biennial Rivkin Center Ovarian Cancer Research Symposium.
Katherine B Chiappinelli, Elizabeth L Christie, Achuth Padmanabhan

Gynecol Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma.
Dale Garsed, Tibor Zwimpfer, Sian Fereday, Ahwan Pandey, Dinuka Ariyaratne, Elizabeth Christie

Res Sq· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploiting dysregulated iron homeostasis to eradicate persistent high-grade serous ovarian cancer.
Carmelo Cerra, Madeleine R C Tancock, Niko Thio, Ada Koo, AnnRann Wong, Elizabeth L Christie

Cell Death Discov· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond deficiency: Clinical and molecular predictors of survival in patients with -deficient tubo-ovarian high-grade serous carcinoma.
Tibor A Zwimpfer, Sian Fereday, Ahwan Pandey, Dinuka Ariyaratne, Madawa W Jayawardana, Elizabeth L Christie

medRxiv· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genome doubling fuels ovarian cancer evolution and immune dysregulation.
Nikki L Burdett, Elizabeth L Christie

Nature· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenic cryptic peptides dominate the antigenic landscape of ovarian cancer.
Remya Raja, Kiran K Mangalaparthi, Anil K Madugundu, Erik Jessen, Latha Pathangey, Elizabeth Christie

Sci Adv· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma.
Flurina A M Saner, Kazuaki Takahashi, Timothy Budden, Ahwan Pandey, Dinuka Ariyaratne, Elizabeth L Christie

Clin Cancer Res· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Timing of whole genome duplication is associated with tumor-specific MHC-II depletion in serous ovarian cancer.
Nikki L Burdett, Madelynne O Willis, Ahwan Pandey, Laura Twomey, Sara Alaei, Elizabeth L Christie

Nat Commun· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Convergent insulin and TGF-β signalling drives cancer cachexia by promoting aberrant fat body ECM accumulation in a Drosophila tumour model.
Daniel Bakopoulos, Sofya Golenkina, Callum Dark, Elizabeth L Christie, Besaiz J Sánchez-Sánchez

EMBO Rep· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer.
Nikki L Burdett, Madelynne O Willis, Ahwan Pandey, Sian Fereday, , Elizabeth L Christie

Sci Rep· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concurrent RB1 loss and -deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinoma.
Flurina A M Saner, Kazuaki Takahashi, Timothy Budden, Ahwan Pandey, Dinuka Ariyaratne, Elizabeth L Christie

medRxiv· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models.
Gwo Yaw Ho, Cassandra J Vandenberg, Ratana Lim, Elizabeth L Christie, Dale W Garsed

Ther Adv Med Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interferon-ε is a tumour suppressor and restricts ovarian cancer.
Zoe R C Marks, Nicole K Campbell, Niamh E Mangan, Cassandra J Vandenberg, Linden J Gearing, Elizabeth L Christie

Nature· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biological-physical interactions are fundamental to understanding and managing coastal dynamics.
Martin Solan, Tom Spencer, David M Paterson, Christopher A Unsworth, Elizabeth K Christie

R Soc Open Sci· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes.
Paula Cunnea, Edward W Curry, Elizabeth L Christie, Katherine Nixon, Chun Hei Kwok

Cell Rep Med· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estrogen receptor beta expression in triple negative breast cancers is not associated with recurrence or survival.
Elena A Takano, Melissa M Younes, Katie Meehan, Lisa Spalding, Max Yan, Elizabeth L Christie

BMC Cancer· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer.
Nikki L Burdett, Madelynne O Willis, Kathryn Alsop, Allison L Hunt, Ahwan Pandey, Elizabeth L Christie

Nat Genet· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer.
Dale W Garsed, Ahwan Pandey, Sian Fereday, Catherine J Kennedy, Kazuaki Takahashi, Elizabeth L Christie

Nat Genet· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members.
Rachel Delahunty, Linh Nguyen, Stuart Craig, Belinda Creighton, Dinuka Ariyaratne, Elizabeth Christie, Christie Norris

J Clin Oncol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phenotypic Consequences of Fusions beyond Drug Resistance in High-Grade Serous Ovarian Cancer.
Kathleen I Pishas, Karla J Cowley, Ahwan Pandey, Therese Hoang, Jessica A Beach, Elizabeth L Christie

Cancers (Basel)· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor-derived MMPs regulate cachexia in a Drosophila cancer model.
William Lodge, Michael Zavortink, Sofia Golenkina, Francesca Froldi, Callum Dark, Elizabeth L Christie

Dev Cell· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer.
Aritro Nath, Patrick A Cosgrove, Hoda Mirsafian, Elizabeth L Christie, Lance Pflieger

Nat Commun· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer.
Natasha Rinne, Elizabeth L Christie, Anastasia Ardasheva, Chun Hei Kwok, Nikita Demchenko

Cancer Drug Resist· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models.
Emma Morrish, Anthony Copeland, Donia M Moujalled, Jason A Powell, Natasha Silke, Elizabeth L Christie

Blood Adv· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis